Press release

Cmed Selected by Spago Nanomedical AB for First Clinical Trial with Tumorad®

Spago Nanomedical AB has announced it has signed an agreement with the Cmed Group for the development of the first clinical study to assess safety and demonstrate proof-of-concept in aggressive cancer patients with the company’s therapy project Tumorad®.

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors.

Press release by Spago Nanomedical AB